August 29, 2018
FDA proposes not including three bulk drug substances that outsourcing facilities may use in compounding
Editor's Note
The Food and Drug Administration (FDA) on August 28 issued a notice proposing not to include three bulk FDA-approved drug substances−bumetanide, nicardipine hydrochloride, and vasopressin−on the list that outsourcing facilities may use in compounding drug products.
The FDA is seeking public comment before finalizing their decision. Comments must be received by October 29, 2018.
Free Daily News
- OR leaders must sharpen questions, partnerships as AI reshapes perioperative care
- npj Digital Surgery opens call for research on AI, robotics in the OR
- AI in the OR can sharpen skills, but humans make the lessons stick
- Endoscopy case highlights risks of complex patients in ASCs
- Robotics and AI are redefining precision in cataract surgery
- CMS plan to phase out inpatient only list sparks debate over safety for vulnerable patients
- ACS issues new best practices for managing genitourinary trauma
- Complex aortic surgery shown safe with minimally invasive approach
- Drug that makes tumors glow is transforming cancer surgery
- Surgical robotics market accelerates as new players challenge industry giants
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement